Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Editas Medicine (NAS:EDIT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Editas Medicine Net Cash per Share Related Terms
Editas Medicine Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDIT vs EVMN, PRTA, CCCC: Net Cash per Share Comparison
For the Biotechnology subindustry, Editas Medicine's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Editas Medicine's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a Net Cash per Share of $0.52 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #401 out of 772 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Editas Medicine's Net Cash per Share too high?
Editas Medicine's current Net Cash per Share is $0.52. The Biotechnology industry median Net Cash per Share is 4.92. Editas Medicine's value of $0.52 is 89.4% below this industry median. Based on the distribution chart, Editas Medicine ranks #401 out of 772 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Net Cash per Share compare to EVMN and PRTA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #401 out of 772 companies for Net Cash per Share. This places Editas Medicine in the lower half of its industry. The industry median Net Cash per Share is 4.92. Editas Medicine's value of $0.52 is 89.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.92, based on 772 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Net Cash per Share of $0.52 is 89.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Net Cash per Share is $0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.07, compared to a current price of $2.69 — trading 30% above its estimated fair value. The current Net Cash per Share is $0.52 and 89.4% below the Biotechnology industry median of 4.92. Editas Medicine's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Net Cash per Share is $0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.69 is trading 30% above its estimated GF Value™ of $2.07.
GuruFocus considers Editas Medicine to be Modestly Overvalued.
Key valuation signals for EDIT:
Net Cash per Share: $0.52
GF Value™: $2.07 vs. price of $2.69 (30% above fair value)
Industry Position: 89.4% below the Biotechnology median (#401 of 772)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
56GF Score
Get the complete analysis for EDIT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
